Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 14;11(11):ofae622.
doi: 10.1093/ofid/ofae622. eCollection 2024 Nov.

Evaluation of Primary Oral Vancomycin Prophylaxis Against Clostridioides difficile Infection During Autologous Stem Cell Transplantation

Michael J Williams  1   2 , Sol Atienza  2 , Erin Franzen  2 , Heena Rathod  2 , Brittany Mejaki  1   2 , Justin Graff  1   2 , Sandra Korman  3 , Noah Zouine  3 , Zartash Gul  1 , Sherjeel Sana  1 , Stephen Medlin  1 , Brian P Buggy  4
Affiliations

Evaluation of Primary Oral Vancomycin Prophylaxis Against Clostridioides difficile Infection During Autologous Stem Cell Transplantation

Michael J Williams et al. Open Forum Infect Dis. .

Abstract

Background: Evaluations of oral vancomycin prophylaxis (OVP) against Clostridioides difficile have been reported in stem cell transplant populations with short follow-up periods. The longest known duration of standardized follow-up post-OVP is 90 days within an allogeneic stem cell transplant population. In 2017, we implemented OVP 125 mg twice daily in autologous stem cell transplant (ASCT) recipients beginning the day of admission and continued until the day of discharge.

Methods: Patients who received an ASCT within our institution between 1 January 2012 and 31 December 2021 were included and separated into 2 groups based on the receipt of OVP. The primary study aim was to measure the incidence of C difficile infection (CDI) during the ASCT admission. A secondary aim was to evaluate for delayed CDI 180 days post-discharge. Other factors evaluated were prior history of CDI, use of systemic antimicrobials, and length of stay.

Results: Overall, 254 patients were evaluated and 58% received OVP, predominantly as primary prophylaxis (95%). Of the 18 patients who developed in-hospital CDI, 6 were in the OVP group versus 12 in the non-OVP cohort (4% vs 11%, P = .03). In the 180-day follow-up period, OVP use did not increase risk of developing CDI after discontinuation while in-hospital length of stay was identified as a significant factor.

Conclusions: The use of OVP significantly reduced the incidence of CDI during the in-hospital ASCT course without increasing CDI post-OVP use. These encouraging results should promote further research into the use of OVP in ASCT.

Keywords: Clostridioides difficile infection; autologous stem cell transplantation; oral vancomycin prophylaxis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: No reported conflicts of interest.

Figures

Figure 1.
Figure 1.
Incidence of Clostridioides difficile infection (CDI) during autologous stem cell transplant (ASCT) admission and 180-day post-discharge follow-up period between the oral vancomycin prophylaxis (OVP) and no-OVP groups. Significant P value is displayed in bold type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Krishna SG, Zhao W, Apewokin SK, Krishna K, Chepyala P, Anaissie EJ. Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients. Transpl Infect Dis 2013; 15:493–501. - PubMed
    1. Shestovska Y, Sorrentino M, Styler MJ, et al. Safety and efficacy of oral vancomycin prophylaxis against Clostridioides difficile infection in stem cell transplant recipients. Transplant Cell Ther 2023; 29:S114–5.
    1. Ganetsky A, Han JH, Hughes ME, et al. Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Clin Infect Dis 2019; 68:2003–9. - PMC - PubMed
    1. Morrisette T, Van Matre AG, Miller MA, et al. Oral vancomycin prophylaxis as secondary prevention against Clostridioides difficile infection in the hematopoietic stem cell transplantation and hematologic malignancy population. Biol Blood Marrow Transplant 2019; 25:2091–7. - PubMed
    1. Altemeier OJ, Konrardy KT. Oral vancomycin for Clostridioides difficile prophylaxis in allogenic hematopoietic cell transplant. Transpl Infect Dis 2022; 24:e13790. - PubMed